Krystal Biotech Reports Over 80% Lesion Regression in KB113 Pilot
Krystal Biotech said more than 80% of assessed basal cell carcinoma lesions regressed in a three-patient Gorlin syndrome pilot study of KB113.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.